Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 11/20 | 0.60 |
| ▸ | NPC1 | O15118 | 9/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19994395 | 1.00 | MAPT (0.66) | MAPTL3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11938403 | 0.87 | L3MBTL1 (0.57) | MAPTL3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1691061 | 0.86 | MAPT (0.68) | MAPTL3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10816647 | 0.86 | RAB9A (0.71) | MAPTL3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2631600 | 0.82 | MAPT (0.64) | MAPTL3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3699546 | 0.82 | MAPT (0.64) | MAPTL3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5630056 | 0.82 | MAPT (0.64) | MAPTL3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL27224565 | 0.82 | SMN1; SMN2 (0.66) | MAPTRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL5335117 | 0.82 | SMN1; SMN2 (0.61) | MAPTRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL16607176 | 0.81 | MAPT (0.80) | MAPTRAB9ANPC1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | claimed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | claimed |
| CN-1906155-B | Novel hydroxamic acid ester derivant and pharmaceutical use thereof | LEO PHARMA AS | 2010-06-23 | — | — | CN | claimed |
| US-20090233975-A1 | Hair resiliency/body improver and hair cosmetic | SHISEIDO COMPANY, LTD. (JP) | 2009-09-17 | — | — | US | claimed |
| EP-1911750-A1 | AGENT FOR IMPROVEMENT IN BOUNCE/BODY OF HAIR, AND HAIR COSMETIC | Shiseido Company, Limited (JP) | 2008-04-16 | — | — | EP | claimed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | claimed |
| JP-2007513098-A | — | — | 2007-05-24 | — | — | JP | claimed |
| EP-1697312-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| EP-0888310-B1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | EP | claimed |
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | claimed |
| EP-0912557-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-06 | — | — | EP | claimed |
| EP-0888310-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1999-01-07 | — | — | EP | claimed |
| WO-1998013350-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | claimed |
| WO-1997042187-A1 | OXINDOLE DERIVATIVES | ZENECA LIMITED (GB) | 1997-11-13 | — | — | WO | claimed |
| WO-1997034876-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1997-09-25 | — | — | WO | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673784-A2 | Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salts, morpholine, thiazole, thiazolidine, thiadiazole, and phenothiazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233975-A1 | Hair resiliency/body improver and hair cosmetic | MC1R, PNISR, HCRTR1 | MAPT 1644/4885L3MBTL1 4514/4885RAB9A 3630/4885 |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | MAPT 4681/4885L3MBTL1 1886/4885RAB9A 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.